Bcl-2 expression inversely correlates with tumour cell differentiation in medulloblastoma

被引:22
作者
Schüller, U
Schober, F
Kretzschmar, HA
Herms, J
机构
[1] Univ Munich, Inst Neuropathol, D-81377 Munich, Germany
[2] Klinikum Ernst Von Bergmann, Inst Pathol, Potsdam, Germany
关键词
age; apoptosis; cerebellum; desmoplastic; immunohistochemistry; prognosis; survival; synaptophysin;
D O I
10.1111/j.1365-2990.2004.00553.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Medulloblastoma (MB) is a cerebellar primitive neuroectodermal tumour that occurs predominantly in childhood. It can be mainly divided into classical and desmoplastic tumours, but differential diagnosis is often difficult. Patients' prognosis is poor and neuropathological markers that reliably predict outcome are still missing. In a series of 104 MBs including 80 tumours of the classical and 24 tumours of the desmoplastic variant we studied the number of apoptotic figures and the expression of the proto-oncogene bcl-2, an anti-apoptotic protein known to affect tumour cell proliferation. We observed a strong correlation between the expression of bcl-2 with patients' age (P < 0.001) as well as with the desmoplastic subtype (P < 0.001). Here, protein expression was found to be restricted to internodular, less differentiated, highly proliferative areas. In classical MB, bcl-2 was detected only in 23% of cases and was highly inversely correlated with the expression of synaptophysin (P < 0.001) indicating that bcl-2 is predominantly expressed by undifferentiated classical MB. With regard to prognosis the expression of bcl-2 tended to correlate with poor outcome in classical MB but not in desmoplastic MB, although not to a statistically significant extension (P = 0.06). On the other hand, a high number of apoptotic figures in the tumour tissue was found to indicate poor prognosis independent of the histological subtype (P < 0.05).
引用
收藏
页码:513 / 521
页数:9
相关论文
共 39 条
[1]   Apoptotic activity and bcl-2 immunoreactivity in meningiomas - Association with grade and outcome [J].
Abramovich, CM ;
Prayson, RA .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 114 (01) :84-92
[2]  
[Anonymous], 2000, World Health Organisation Classification of Tumours: Pathology and genetics of tumours of the nervous system
[3]   PROSPECTIVE RANDOMIZED TRIAL OF CHEMOTHERAPY GIVEN BEFORE RADIOTHERAPY IN CHILDHOOD MEDULLOBLASTOMA - INTERNATIONAL-SOCIETY-OF-PEDIATRIC-ONCOLOGY (SIOP) AND THE (GERMAN)-SOCIETY-OF-PEDIATRIC-ONCOLOGY (GPO) - SIOP-II [J].
BAILEY, CC ;
GNEKOW, A ;
WELLEK, S ;
JONES, M ;
ROUND, C ;
BROWN, J ;
PHILLIPS, A ;
NEIDHARDT, MK .
MEDICAL AND PEDIATRIC ONCOLOGY, 1995, 25 (03) :166-178
[4]  
Bühren J, 2000, J NEUROPATH EXP NEUR, V59, P229
[5]   A REVIEW OF THE FACTORS INFLUENCING THE PROGNOSIS OF MEDULLOBLASTOMA - THE IMPORTANCE OF CELL-DIFFERENTIATION [J].
CAPUTY, AJ ;
MCCULLOUGH, DC ;
MANZ, HJ ;
PATTERSON, K ;
HAMMOCK, MK .
JOURNAL OF NEUROSURGERY, 1987, 66 (01) :80-87
[6]  
CASTLE VP, 1993, AM J PATHOL, V143, P1543
[7]   Apoptosis, neuronal maturation, and neurotrophin expression within medulloblastoma nodules [J].
Eberhart, CG ;
Kaufman, WE ;
Tihan, T ;
Burger, PC .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (05) :462-469
[8]   What's new in neuro-oncology? Recent advances in medulloblastoma [J].
Ellison, DW ;
Clifford, SC ;
Gajjar, A ;
Gilbertson, RJ .
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2003, 7 (02) :53-66
[9]   THE TREATMENT OF MEDULLOBLASTOMA - RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL OF RADIATION-THERAPY WITH AND WITHOUT CCNU, VINCRISTINE, AND PREDNISONE [J].
EVANS, AE ;
JENKIN, RDT ;
SPOSTO, R ;
ORTEGA, JA ;
WILSON, CB ;
WARA, W ;
ERTEL, IJ ;
KRAMER, S ;
CHANG, CH ;
LEIKIN, SL ;
HAMMOND, GD .
JOURNAL OF NEUROSURGERY, 1990, 72 (04) :572-582
[10]   Medulloblastoma with extensive nodularity:: a variant with favorable prognosis [J].
Giangaspero, F ;
Perilongo, G ;
Fondelli, MP ;
Brisigotti, M ;
Carollo, C ;
Burnelli, R ;
Burger, PC ;
Garrè, ML .
JOURNAL OF NEUROSURGERY, 1999, 91 (06) :971-977